Multiple Sclerosis: Pathogenesis and Treatment
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the central nervous system. It affects approximately 400,000 people in the United States and onset is usually during young adulthood. There are four clinical forms of MS, of which relapsing remitting type is the most common. As the etiology of MS is unknown, finding a cure will remain challenging. The main mechanism of injury appears to be inflammation and 8 agents are now FDA approved to help control MS. These agents for relapsing forms of MS target different parts of the immune system, with the end goal of decreasing and avoiding further inflammation. No agents are FDA approved for the primary progressive version of MS. FDA approved agents include four preparations of interferon β (Avonex, Rebif, Betaseron and Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri) and fingolimod (Gilenya). There are several drug undergoing phase II and III trials. The heterogeneity of the MS disease process, individual patient response, and medication toxicities continue to challenge the treating physician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., & Iwakura, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.566 · Cited by 1,536
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154 · cited 2×
“lapse rate, decrease disability progression, and MRI evidence of disease activity [19].”
BackgroundA Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,023
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Multiple sclerosis: Geoepidemiology, genetics and the environment
Milo, R., & Kahana, E. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.11.010 · Cited by 680
Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease
Fujinami, R. S., von Herrath, M. G., Christen, U., & Whitton, J. L. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.80-94.2006 · Cited by 679
Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., Kim, H. J., & Bar-Or, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6092 · Cited by 653
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Yang, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 482
Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C. S., Filser, A., Vetter, T., Milkova, L., Korporal, M., Fritz, B., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526065 · Cited by 449
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
O’Connor, P. W., Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P. A., Confavreux, C., Paty, D. W., Stewart, J. A., & Scheyer, R. (2006) · Neurology · doi:10.1212/01.wnl.0000203121.04509.31 · Cited by 358
Cladribine (2-chlorodeoxyadenosine)
Beutler, E. (1992) · The Lancet · doi:10.1016/0140-6736(92)92826-2 · Cited by 348
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Zivadinov, R., Rudick, R. A., De Masi, R., Nasuelli, D., Ukmar, M., Pozzi–Mucelli, R. S., Grop, A., Cazzato, G., & Zorzon, M. (2001) · Neurology · doi:10.1212/wnl.57.7.1239 · Cited by 346
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., et al. (1998) · Neurology · doi:10.1212/wnl.50.5.1266 · Cited by 333
Role of the innate immune system in the pathogenesis of multiple sclerosis
Gandhi, R., Laroni, A., & Weiner, H. L. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.015 · Cited by 331
Interferon-β mechanisms of action in multiple sclerosis
Dhib-Jalbut, S., & Marks, S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97d99 · Cited by 298
HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease Course
Barcellos, L. F., Oksenberg, J. R., Begovich, A. B., Martin, E. R., Schmidt, S., Vittinghoff, E., Goodin, D. S., Pelletier, D., Lincoln, R. R., Bucher, P., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/367781 · Cited by 293
Weiner, H. L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1002-8 · Cited by 255
Rituximab-Associated Infections
Gea-Banacloche, J. C. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.002 · Cited by 251
Achiron, A., Kishner, I., Dolev, M., Stern, Y., Dulitzky, M., Schiff, E., & Achiron, R. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0495-z · Cited by 215
Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis
Tennakoon, D. K., Mehta, R. S., Ortega, S. B., Bhoj, V., Racke, M. K., & Karandikar, N. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.7119 · Cited by 207
Kimura, A., Ohmori, T., Ohkawa, R., Madoiwa, S., Mimuro, J., Murakami, T., Kobayashi, E., Hoshino, Y., Yatomi, Y., & Sakata, Y. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0223 · Cited by 202
Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H.-P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70103-4 · Cited by 198
Multiple sclerosis immunology: The healthy immune system vs the MS immune system
Kasper, L. H., & Shoemaker, J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97c8f · Cited by 166
Yeh, E. A., Chitnis, T., Krupp, L., Ness, J., Chabas, D., Kuntz, N. L., & Waubant, E. L. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.158 · Cited by 158
Mitoxantrone for multiple sclerosis
Martinelli Boneschi, F., Vacchi, L., Rovaris, M., Capra, R., & Comi, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002127.pub3 · Cited by 156
de Andrés, C., Aristimuño, C., Heras, V. D. L., Martínez-Ginés, M. L., Bartolomé, M., Arroyo, R., Navarro, J., Giménez-Roldán, S., Fernández‐Cruz, E., & Sánchez‐Ramón, S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.09.012 · Cited by 153
Clinical implications of a possible role of vitamin D in multiple sclerosis
Pierrot‐Deseilligny, C. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5139-x · Cited by 141
The mechanism of action of glatiramer acetate treatment in multiple sclerosis
Racke, M. K., Lovett‐Racke, A. E., & Karandikar, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c97e39 · Cited by 134
Haas, J., Korporal, M., Balint, B., Fritzsching, B., Schwarz, A., & Wildemann, B. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.06.011 · Cited by 119
Sørensen, P. S., Fazekas, F., & Lee, M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00501.x · Cited by 119
Goldberg, L., Edwards, N. C., Fincher, C., Doan, Q. V., Al‐Sabbagh, A., & Meletiche, D. M. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.7.543 · Cited by 116
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis
Fazekas, F., LUBLIN, F. D., Li, D., Freedman, M. S., Hartung, H., Rieckmann, P., Sørensen, P. S., Maas-Enríquez, M., Sommerauer, B., & Hanna, K. (2008) · Neurology · doi:10.1212/01.wnl.0000318281.98220.6f · Cited by 115
Monoclonal antibodies in MS: Mechanisms of action
Bielekova, B., & Becker, B. L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97ed3 · Cited by 110
Cytokine networks in multiple sclerosis: lost in translation
Deak, L. C., Fontana, A., & Becher, B. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283391feb · Cited by 105
Chitnis, T., Krupp, L., Yeh, E. A., Rubin, J. P., Kuntz, N. L., Strober, J. B., Chabas, D., Weinstock‐Guttmann, B., Ness, J., Rodriguez, M., et al. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2011.01.004 · Cited by 99
Liver injury associated with the β-interferons for MS
Tremlett, H. L., Yoshida, E. M., & Oger, J. (2004) · Neurology · doi:10.1212/wnl.62.4.628 · Cited by 83
Corticosteroids for the long-term treatment in multiple sclerosis
Ciccone, A., Beretta, S., Brusaferri, F., Galea, I., Protti, A., & Spreafico, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006264.pub2 · Cited by 78
Mitoxantrone for multiple sclerosis
Boneschi, F. M., Rovaris, M., Capra, R., & Comı, G. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002127.pub2 · Cited by 72
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
BOURDETTE, D. N., & Yadav, V. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0064-4 · Cited by 69
Tallantyre, E. C., Evangelou, N., & Constantinescu, C. S. (2008) · PubMed · Cited by 60
Methotrexate for multiple sclerosis
Gray, O. M., McDonnell, G. V., & Forbes, R. B. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003208.pub2 · Cited by 52
Mitoxantrone and cytotoxic drugs' mechanisms of action
Vollmer, T. R., Stewart, T., & Baxter, N. N. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c97f5a · Cited by 48
Alemtuzumab and multiple sclerosis: therapeutic application
Minagar, A., Steven, A. J., Sahraian, M. A., & Zivadinov, R. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003586806 · Cited by 42
Emerging multiple sclerosis oral therapies
Rammohan, K. W., & Shoemaker, J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c97f89 · Cited by 39
Daclizumab for relapsing remitting multiple sclerosis
Liu, J., Wang, L., Zhan, S., & Xia, Y. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008127.pub4 · Cited by 22
B cells as a target of immune modulation
Hawker, K. (2009) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.58275 · Cited by 11
Cited by
Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.
Ghasemi, N., Razavi, S., & Nikzad, E. (2016) · PubMed · doi:10.22074/cellj.2016.4867 · Cited by 685
Multiple sclerosis prevalence in the United States commercially insured population
Dilokthornsakul, P., Valuck, R. J., Nair, K. V., Corboy, J. R., Allen, R. R., & Campbell, J. D. (2016) · Neurology · doi:10.1212/wnl.0000000000002469 · Cited by 273
Lopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
The benefits and detriments of macrophages/microglia in models of multiple sclerosis
Rawji, K. S., & Yong, V. W. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/948976 · Cited by 217
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Metadata
- Authors
- Loma, I., & Heyman, R.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-09-01
- Volume
- 9
- Issue
- 3
- Pages
- 409-416
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2031358440
- Cited by
- 350
- References
- 50
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.